Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Heron Therapeutics stock | $10.82

Learn how to easily invest in Heron Therapeutics stock.

Heron Therapeutics Inc is a biotechnology business based in the US. Heron Therapeutics shares (HRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Heron Therapeutics employs 223 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Heron Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – HRTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Heron Therapeutics stock price (NASDAQ: HRTX)

Use our graph to track the performance of HRTX stocks over time.

Heron Therapeutics shares at a glance

Information last updated 2021-10-23.
Latest market close$10.82
52-week range$9.87 - $22.40
50-day moving average $11.22
200-day moving average $13.58
Wall St. target price$33.17
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.52

Buy Heron Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
Get two free stocks valued between $3.00 and $300 with a deposit to any new account.
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Heron Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Heron Therapeutics price performance over time

Historical closes compared with the close of $10.82 from 2021-10-27

1 week (2021-10-21) 6.39%
1 month (2021-09-28) -8.69%
3 months (2021-07-28) -14.60%
6 months (2021-04-28) -41.20%
1 year (2020-10-27) -31.91%
2 years (2019-10-25) -45.38%
3 years (2018-10-26) 27.59
5 years (2016-10-27) 15.35

Heron Therapeutics financials

Revenue TTM $83 million
Gross profit TTM $-120,884,000
Return on assets TTM -33.85%
Return on equity TTM -96.72%
Profit margin -281.99%
Book value $1.57
Market capitalisation $1.1 billion

TTM: trailing 12 months

Shorting Heron Therapeutics shares

There are currently 26.9 million Heron Therapeutics shares held short by investors – that's known as Heron Therapeutics's "short interest". This figure is 2% up from 26.4 million last month.

There are a few different ways that this level of interest in shorting Heron Therapeutics shares can be evaluated.

Heron Therapeutics's "short interest ratio" (SIR)

Heron Therapeutics's "short interest ratio" (SIR) is the quantity of Heron Therapeutics shares currently shorted divided by the average quantity of Heron Therapeutics shares traded daily (recently around 1.1 million). Heron Therapeutics's SIR currently stands at 24.18. In other words for every 100,000 Heron Therapeutics shares traded daily on the market, roughly 24180 shares are currently held short.

However Heron Therapeutics's short interest can also be evaluated against the total number of Heron Therapeutics shares, or, against the total number of tradable Heron Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Heron Therapeutics's short interest could be expressed as 0.26% of the outstanding shares (for every 100,000 Heron Therapeutics shares in existence, roughly 260 shares are currently held short) or 0.3019% of the tradable shares (for every 100,000 tradable Heron Therapeutics shares, roughly 302 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Heron Therapeutics.

Find out more about how you can short Heron Therapeutics stock.

Heron Therapeutics share dividends

We're not expecting Heron Therapeutics to pay a dividend over the next 12 months.

Have Heron Therapeutics's shares ever split?

Heron Therapeutics's shares were split on a 1:20 basis on 12 January 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heron Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Heron Therapeutics shares which in turn could have impacted Heron Therapeutics's share price.

Heron Therapeutics share price volatility

Over the last 12 months, Heron Therapeutics's shares have ranged in value from as little as $9.87 up to $22.4. A popular way to gauge a stock's volatility is its "beta".

HRTX.US volatility(beta: 1.38)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heron Therapeutics's is 1.3836. This would suggest that Heron Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Heron Therapeutics overview

Heron Therapeutics, Inc. , a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A. P.

Frequently asked questions

What percentage of Heron Therapeutics is owned by insiders or institutions?
Currently 0.163% of Heron Therapeutics shares are held by insiders and 104.666% by institutions.
How many people work for Heron Therapeutics?
Latest data suggests 223 work at Heron Therapeutics.
When does the fiscal year end for Heron Therapeutics?
Heron Therapeutics's fiscal year ends in December.
Where is Heron Therapeutics based?
Heron Therapeutics's address is: 4242 Campus Point Court, San Diego, CA, United States, 92121
What is Heron Therapeutics's ISIN number?
Heron Therapeutics's international securities identification number is: US4277461020
What is Heron Therapeutics's CUSIP number?
Heron Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00202J104

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site